Brain-Life
Brain-Life is a neuroscience-focused AI company developing digital therapeutics for neurodegenerative diseases.
Profile
Develops AI-powered therapeutics for neurodegenerative diseases and brain cancers.
Brain-Life is a neuroscience-focused AI company developing digital therapeutics for neurodegenerative diseases. Founded in the early 2020s, the company has positioned itself at the intersection of clinical neurology and machine learning, though specific founding details and headquarters location remain undisclosed in available materials. Its core offering appears to be a proprietary AI platform targeting conditions like Alzheimer's, with recent developments suggesting expansion into glioblastoma treatment based on GLIX1 clinical trials.
The company operates in a high-stakes therapeutic area where more than 7 million Americans live with Alzheimer's alone, representing a $409 billion healthcare cost burden in 2026 according to Alzheimer's Association data. Financial visibility is limited, but the neuroscience sector shows momentum with Neurocrine Biosciences reporting 44% year-over-year growth to $811M in Q1 2026 net product sales, indicating market appetite for neurological treatments. Brain-Life's recent Phase 1/2a trial initiation for GLIX1 in glioblastoma, conducted at NYU Langone Health and other leading cancer centers, marks its most concrete clinical milestone to date. The space remains intensely competitive, with companies like Nuvation Bio reporting $18.5M in Q1 2026 net product revenues for their ROS1+ NSCLC treatment IBTROZI, demonstrating the revenue potential for targeted neurological therapies.
Who buys this
- Neurology departments at academic medical centers
- Oncology treatment centers specializing in glioblastoma
- Pharmaceutical companies seeking neurology-focused AI platforms
- Healthcare systems investing in digital therapeutics
Strengths and what to watch
Strengths
- Clinical validation through Phase 1/2a trials at NYU Langone and other top cancer centers
- Focus on high-unmet-need conditions like glioblastoma with TMZ-resistant patient models
- Partnerships with neuro-oncology leaders like Dr. Alexandra Miller at NYU
Watch for
- Limited financial disclosure compared to public peers like Neurocrine Biosciences
- Dependence on single asset GLIX1 in early-stage trials
- Intense competition from well-funded neurology players like Nuvation Bio
Recent moves
Key Information
- Founded
- 2020
Frequently Asked Questions
What does Brain-Life do?
Brain-Life develops AI-powered digital therapeutics for neurodegenerative diseases and brain cancers. Their proprietary AI platform targets conditions like Alzheimer's, with recent expansion into glioblastoma treatment through GLIX1 clinical trials. The company focuses on high-unmet-need neurological conditions.
What is GLIX1 and what does it treat?
GLIX1 is Brain-Life's experimental treatment targeting glioblastoma, a type of brain cancer. The therapy is currently in Phase 1/2a clinical trials conducted at NYU Langone Health and other leading cancer centers, focusing on TMZ-resistant patient models.
Who are Brain-Life's primary customers?
Brain-Life serves neurology departments at academic medical centers, oncology treatment centers specializing in glioblastoma, pharmaceutical companies seeking neurology-focused AI platforms, and healthcare systems investing in digital therapeutics.
What makes Brain-Life's approach unique?
Brain-Life combines clinical neurology with machine learning to develop AI-powered therapeutics. Their focus on high-unmet-need conditions like glioblastoma and Alzheimer's, supported by Phase 1/2a trials at top cancer centers, sets them apart in the neuroscience space.
What are the latest developments in Brain-Life's GLIX1 trials?
Brain-Life recently dosed the first patient in its Phase 1/2a trial for GLIX1, targeting glioblastoma. The trial is being conducted at NYU Langone Health and other leading cancer centers, marking a significant milestone in their clinical validation process.
How does Brain-Life compare to competitors in neurology?
Brain-Life operates in a competitive landscape with companies like Nuvation Bio. While Brain-Life focuses on AI-powered therapeutics for neurodegenerative diseases and glioblastoma, competitors like Nuvation Bio target different neurological conditions, highlighting the diverse approaches in this high-stakes therapeutic area.
Sources
- www.prnewswire.com — GLIX1 clinical trial details
- www.alz.org — Alzheimer's disease market size
- www.prnewswire.com — Neurology market growth benchmarks
- www.prnewswire.com — Competitive landscape in neurological therapies